Copy to clipboard 
ORTHOWORLD estimates Zimmer Biomet 1Q17 orthopaedic revenue of US $1,836.1MM, +4.9% from 1Q16. Estimated segment sales and growth follow.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $1,279.9 | $1,267.9 | $12.0 | 1.0% |
| Knee | $701.8 | $703.3 | -$1.5 | -0.2% |
| Hip | $475.7 | $467.9 | $7.8 | 1.7% |
| Extremities | $102.4 | $96.7 | $5.8 | 6.0% |
| Spine | $97.7 | $70.7 | $27.0 | 38.1% |
| Trauma | $138.5 | $130.4 | $8.1 | 6.2% |
| Arthroscopy/Soft Tissue | $31.3 | $30.1 | $1.2 | 4.1% |
| Orthobiologics | $73.4 | $70.0 | $3.4 | 4.9% |
| Other* | $215.1 | $181.7 | $33.5 | 18.4% |
| Total | $1,836.1 | $1,750.8 | $85.3 | 4.9% |
*Contains CMF, Bone Healing, Forgings, Accelero
- Experienced greater-than-expected production delays in 1Q while implementing operational process improvements at Warsaw North Campus manufacturing facility, though overall production improved during 1Q (affecting manufacture of the Persona knee and legacy Biomet hips, and the Comprehensive Shoulder to a lesser degree)
- This progress supports an anticipated restoration of supply and growth of affected products in 2H17
- Pricing in 1Q: Knees -2.4%, hips -3.2%
- Geographic growth update:
- Knees: Americas -0.1%, EMEA -3.4%, Asia Pacific +5.0%
- Hips: Americas +0.2%, EMEA -0.5%, Asia Pacific +9.5%
- Shared an in-depth look at Signature Solutions at AAOS; will further develop and commercialize that offering during 2017
- Knee sales supported by Oxford Partial Knee and Persona; full commercial launch of Persona partial knee slated for 2H17
- Robotics application for total knee slated for clinical evaluation stage in 2H18; could see a 2019 launch at AAOS
- Hips driven by Taperloc, G7 Acetabular, G7 Dual Mobility Construct and increased sales of Arcos femoral revision and premium constructs, leveraging 3D-printed OsseoTi metal and vitamin E-infused advanced bearing material
- Demand remains strong for the Comprehensive Total Shoulder
- Spine growth reflects acquisition of Mobi-C plus new products (Vitality fixation)
- Trauma supported by ALPS Proximal Humerus Plate, NCB Periprosthetic femur plate, DVR Crosslock Distal Radius Plate
- AR/ST growth continues to be complemented by sales of Gel-One and Subchondroplasty
- 2017 pipeline at ~40 new products
Sources: Zimmer Biomet, Inc.; ORTHOWORLD estimates
Ranking Recap:
ORTHOWORLD’s 2016 estimates place Zimmer Biomet at #2 in overall orthopaedic revenue (behind market leader DePuy Synthes), #1 in joint reconstruction and #3 in the trauma segment. Review these rankings in your copy of Orthopaedic Device Company Profiles: The Top 5.
ORTHOWORLD estimates Zimmer Biomet 1Q17 orthopaedic revenue of US $1,836.1MM, +4.9% from 1Q16. Estimated segment sales and growth follow.
Q17
Q16
$ Change
% Change
Joint Reconstruction
$1,279.9
$1,267.9 ...
ORTHOWORLD estimates Zimmer Biomet 1Q17 orthopaedic revenue of US $1,836.1MM, +4.9% from 1Q16. Estimated segment sales and growth follow.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $1,279.9 | $1,267.9 | $12.0 | 1.0% |
| Knee | $701.8 | $703.3 | -$1.5 | -0.2% |
| Hip | $475.7 | $467.9 | $7.8 | 1.7% |
| Extremities | $102.4 | $96.7 | $5.8 | 6.0% |
| Spine | $97.7 | $70.7 | $27.0 | 38.1% |
| Trauma | $138.5 | $130.4 | $8.1 | 6.2% |
| Arthroscopy/Soft Tissue | $31.3 | $30.1 | $1.2 | 4.1% |
| Orthobiologics | $73.4 | $70.0 | $3.4 | 4.9% |
| Other* | $215.1 | $181.7 | $33.5 | 18.4% |
| Total | $1,836.1 | $1,750.8 | $85.3 | 4.9% |
*Contains CMF, Bone Healing, Forgings, Accelero
- Experienced greater-than-expected production delays in 1Q while implementing operational process improvements at Warsaw North Campus manufacturing facility, though overall production improved during 1Q (affecting manufacture of the Persona knee and legacy Biomet hips, and the Comprehensive Shoulder to a lesser degree)
- This progress supports an anticipated restoration of supply and growth of affected products in 2H17
- Pricing in 1Q: Knees -2.4%, hips -3.2%
- Geographic growth update:
- Knees: Americas -0.1%, EMEA -3.4%, Asia Pacific +5.0%
- Hips: Americas +0.2%, EMEA -0.5%, Asia Pacific +9.5%
- Shared an in-depth look at Signature Solutions at AAOS; will further develop and commercialize that offering during 2017
- Knee sales supported by Oxford Partial Knee and Persona; full commercial launch of Persona partial knee slated for 2H17
- Robotics application for total knee slated for clinical evaluation stage in 2H18; could see a 2019 launch at AAOS
- Hips driven by Taperloc, G7 Acetabular, G7 Dual Mobility Construct and increased sales of Arcos femoral revision and premium constructs, leveraging 3D-printed OsseoTi metal and vitamin E-infused advanced bearing material
- Demand remains strong for the Comprehensive Total Shoulder
- Spine growth reflects acquisition of Mobi-C plus new products (Vitality fixation)
- Trauma supported by ALPS Proximal Humerus Plate, NCB Periprosthetic femur plate, DVR Crosslock Distal Radius Plate
- AR/ST growth continues to be complemented by sales of Gel-One and Subchondroplasty
- 2017 pipeline at ~40 new products
Sources: Zimmer Biomet, Inc.; ORTHOWORLD estimates
Ranking Recap:
ORTHOWORLD’s 2016 estimates place Zimmer Biomet at #2 in overall orthopaedic revenue (behind market leader DePuy Synthes), #1 in joint reconstruction and #3 in the trauma segment. Review these rankings in your copy of Orthopaedic Device Company Profiles: The Top 5.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
